Sitemize üye olarak beğendiğiniz içerikleri favorilerinize ekleyebilir, kendi ürettiğiniz ya da internet üzerinde beğendiğiniz içerikleri sitemizin ziyaretçilerine içerik gönder seçeneği ile sunabilirsiniz.
Sitemize üye olarak beğendiğiniz içerikleri favorilerinize ekleyebilir, kendi ürettiğiniz ya da internet üzerinde beğendiğiniz içerikleri sitemizin ziyaretçilerine içerik gönder seçeneği ile sunabilirsiniz.
Üyelerimize Özel Tüm Opsiyonlardan Kayıt Olarak Faydalanabilirsiniz
Michael Polansky—better known as Lady Gaga’s partner and a former senior aide to tech entrepreneur Sean Parker—has been quietly building a cutting‑edge biotech venture for several years. The company’s core technology is a bioreactor that can sustain small samples of human skin tissue alive for weeks outside the body, while an artificial‑intelligence platform analyses the tissue to predict how various compounds will interact with it.
In practice, a thin slice of donor skin is placed in a nutrient‑rich chamber that mimics the body’s natural environment, preserving cellular metabolism and barrier function. High‑resolution imaging and molecular profiling feed the data into machine‑learning models that rank thousands of potential active ingredients on efficacy, safety and stability. What traditionally required months of in‑vitro testing can now be narrowed down to a shortlist within days.
Polansky kept the project under wraps for most of its development, sharing details only with a handful of venture investors. This week, however, the startup announced its first external funding round and began speaking publicly about the platform’s promise for the cosmetics industry. Early pilots with a few major skincare brands have already shown that the AI‑driven workflow can cut formulation time by up to 70 percent while improving predictive accuracy.
“The ability to run AI on living skin changes the entire R&D paradigm,” Polansky said in a recent interview. “We can now identify truly effective ingredients before they ever hit a petri dish, reducing risk for both manufacturers and consumers.” The company plans to expand its capabilities into dermatology treatments and personalized skin‑care regimens, positioning the technology as a bridge between biotech research and consumer‑grade products. If successful, this approach could reshape how the beauty industry innovates, delivering safer, more targeted solutions at unprecedented speed.
Source: TechCrunch
ETİKETLER
BENZER İÇERİKLER
OKUYUCU YORUMLARI
Michael Polansky Uses AI on Living Skin to Discover Next-Gen Skincare Ingredients
Yorum Yaz